POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS

被引：0

作者：

Siegel, D. S. ^{[1
]}

Schiller, G. J. ^{[2
]}

Song, K. ^{[3
]}

Agajanian, R. ^{[4
]}

Stockerl-Goldstein, K. ^{[5
]}

Kaya, H. ^{[6
]}

Sebag, M. ^{[7
]}

Reu, F. J. ^{[8
]}

Malek, E. ^{[9
]}

Talamo, G. ^{[10
]}

Mouro, J. ^{[11
]}

Chung, W. ^{[11
]}

Srinivasan, S. ^{[11
]}

Qian, M. ^{[11
]}

Rizvi, S. ^{[11
]}

Thakurta, A. ^{[11
]}

Bahlis, N. J. ^{[12
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Vancouver Gen Hosp, Vancouver, BC, Canada

[4] Oncol Inst Hope & Innovat, Downey, CA USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Canc Care Northwest, Spokane, WA USA

[7] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[8] Cleveland Clin, Cleveland, OH 44106 USA

[9] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA

[10] Penn State Hershey Canc Inst, Hershey, PA USA

[11] Celgene Corp, Summit, NJ USA

[12] Univ Calgary, Calgary, AB, Canada

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1248

引用

页码：511 / 511

页数：1

共 50 条

[1] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.
Siegel, David
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
Siegel, David Samuel DiCapua
Schiller, Gary J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo
Reece, Donna Ellen
Zafar, Faiza
Chung, Weiyuan
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Phase 2 Study of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety
Siegel, David S.
Schiller, Gary J.
Song, Kevin
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Reu, Frederic J.
Malek, Eshan
Mouro, Jorge
Chung, Weiyuan
Srinivasan, Shankar
Qian, Max
Rizvi, Syed
Thakurta, Anjan
Bahlis, Nizar J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E141 - E141
[4] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)
Qian, Xiaozhong
Newhall, Kathryn
Tometsko, Mark
Bjorklund, Chad
Ma, Jianglin
Bahlis, Nizar J.
Siegel, David
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Mouro, Jorge
Agarwal, Amit
Zafar, Faiza
Thakurta, Anjan
BLOOD, 2017, 130
[5] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, Ravi
Richardson, Paul Gerard Guy
Jagannath, Sundar
Siegel, David Samuel DiCapua
Baz, Rachid C.
Srinivasan, Shankar
Larkins, Gail
Zaki, Mohamed H.
Hussein, Mohamad A.
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX)
Siegel, David Samuel DiCapua
Agajanian, Richy
Gaur, Rakesh
Karamiou, Kasra
Kaya, Hakan
Sturniolo, Michael
Ricafort, Rosanna J.
Larkins, Gall
Srinivasan, Shankar
Chopra, Rajosh
Thakurta, Anjan
Nagarwala, Yasir M.
Kruter, Flavio
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Safety and Efficacy of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN) Based Treatment (Tx) Failure
Siegel, David
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Mouro, Jorge
Agarwal, Amit
Zafar, Faiza
Qian, Max
Thakurta, Anjan
Bahlis, Nizar J.
BLOOD, 2017, 130
[8] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)
[9] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
Vij, Ravi
Hofmeister, Craig C.
Richardson, Paul G.
Jagannath, Sundar
Siegel, David S.
Baz, Rachid
Chen, Min
Zaki, Mohamed
Larkins, Gail
Anderson, Kenneth C.
BLOOD, 2012, 120 (21)
[10] Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)
Siegel, David S.
Schiller, Gary
Song, Kevin
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Reu, Frederic J.
Mouro, Jorge
Sturniolo, Michael
Srinivasan, Shankar
Thakurta, Anjan
Nagarwala, Yasir
Bahlis, Nizar J.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →